Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

Infections caused by gram-negative bacteria have features that are of particular concern. These organisms are highly efficient at up-regulating or acquiring genes that code for mechanisms of ...

Multidrug-resistant gram-negative infections (MDRGNIs) are an emerging and deadly threat worldwide. Some of these infections are now resistant to nearly all antibiotics, and very few treatment options ...

Gram-negative meningitis is a form of meningitis. The term gram-negative refers to a way of differentiating bacteria. This type of bacteria is typically resistant to drugs and most available ...

Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...

Urinary tract infections (UTIs) are common, but increasingly hard to treat because the bacteria that cause them are developing resistance to many antibiotics. Researchers headed by a team at the ...

Based on the Company's Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients.

Antibiotic resistance among Gram‐negative bacteria represents one of the most pressing challenges in modern medicine. These pathogens have evolved multiple mechanisms to evade the effects of ...

A salmonella outbreak tied to a powdered greens supplement sold at Sam's Club has sickened at least 11 people across seven states, and three have been hospitalized, U.S. health officials said last ...

Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections Qualified Infectious Disease ...